Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADAG |
---|---|---|
10:51 ET | 849 | 2.6 |
12:34 ET | 800 | 2.6125 |
02:08 ET | 840 | 2.68 |
03:34 ET | 140 | 2.8499 |
03:59 ET | 259 | 2.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adagene Inc | 122.7M | -3.3x | --- |
Clearside Biomedical Inc | 114.3M | -2.9x | --- |
Syros Pharmaceuticals Inc | 137.3M | -0.9x | --- |
NGM Biopharmaceuticals Inc | 132.7M | -0.9x | --- |
Coya Therapeutics Inc | 144.3M | -12.1x | --- |
Molecular Partners AG | 147.9M | -2.0x | --- |
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $122.7M |
---|---|
Revenue (TTM) | $22.7M |
Shares Outstanding | 43.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.85 |
Book Value | $1.92 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | 5.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -180.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.